CHROMOS SIGNS AGREEMENT WITH APPTEC TO MANUFACTURE MULTIPLE SCLEROSIS DRUG
Chromos Molecular Systems has signed a contract with AppTec Laboratory Services for scale-up and manufacture of its monoclonal antibody drug product candidate CHR-1103. Chromos has used its proprietary ACE System to engineer cell lines for CHR-1103; AppTec will scale up and manufacture CHR-1103 for use in preclinical toxicology studies and Phase I clinical trials.
A humanized monoclonal antibody for the treatment of the inflammatory disease, CHR-1103 is being developed initially to treat acute flares associated with relapsing forms of multiple sclerosis (MS). The drug's unique mechanism of action has the potential to reduce the severity of a relapse and stem the residual neurological damage that often accompanies progression of the disease, positioning CHR-1103 to fill an unmet medical need for an effective acute treatment of MS.